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Background: Bangladesh is a malaria hypo-endemic country sharing borders with India and Myanmar. Artemisinin
combination therapy (ACT) remains successful in Bangladesh. An increase of artemisinin-resistant malaria parasites
on the Thai-Cambodia and Thai-Myanmar borders is worrisome. K13 propeller gene (PF3D7_1343700 or PF13_0238)
mutations have been linked to both in vitro artemisinin resistance and in vivo slow parasite clearance rates. This
group undertook to evaluate if mutations seen in Cambodia have emerged in Bangladesh where ACT use is now
standard for a decade.
Methods: Samples were obtained from Plasmodium falciparum-infected malaria patients from Upazila health
complexes (UHC) between 2009 and 2013 in seven endemic districts of Bangladesh. These districts included
Khagrachari (Matiranga UHC), Rangamati (Rajasthali UHC), Cox’s Bazar (Ramu and Ukhia UHC), Bandarban (Lama
UHC), Mymensingh (Haluaghat UHC), Netrokona (Durgapur and Kalmakanda UHC), and Moulvibazar (Sreemangal
and Kamalganj UHC).
Results: Out of 296 microscopically positive P. falciparum samples, 271 (91.6%) were confirmed as mono-infections by
both real-time PCR and nested PCR. The K13 propeller gene from 253 (93.4%) samples was sequenced bi-directionally.
One non-synonymous mutation (A578S) was found in Bangladeshi clinical isolates. The A578S mutation was confirmed
and lies adjacent to the C580Y mutation, the major mutation causing delayed parasite clearance in Cambodia. Based
on computational modeling A578S should have a significant effect on tertiary
structure of the protein.
Conclusion: The data suggest that P. falciparum in Bangladesh remains free of the C580Y mutation linked to delayed
parasite clearance. However, the mutation A578S is present and based on structural analysis could affect K13 gene
function. Further in vivo clinical studies are required to validate the effect of this mutation.Background
The term ‘artemisinin resistance’ in Plasmodium falcip-
arum has not been precisely defined. The clinical inter-
pretation is a relatively slow parasite clearance rate in
patients receiving artemisinin or artemisinin combination
therapy (ACT) [1]. In low malaria transmission areas,
parasite clearance studies require screening of thousands
of febrile individuals to enroll a few patients. Therefore,* Correspondence: drpillai@ucalgary.ca
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unless otherwise stated.these studies can be logistically and financially difficult
and inconvenient for patients [2]. From a biological per-
spective, in vitro studies have sought a suitable molecular
marker to identify artemisinin resistance in P. falciparum
parasites. Mutation and variable expression of several
genes such as PfMDR and PfATPase6 have been suggested
but not proven [3]. Recently, the K13 propeller gene
PF3D7_1343700 (PF13_0238) has been linked to in vitro
artemisinin resistance and in vivo slow parasite clearance
rate and therefore proposed as marker of artemisinin re-
sistance. K13 propeller has been predicted to consist of
three domains 225 amino acid in length: i) Plasmodium-
specific and well conserved N-terminal domain; ii) a BTB/
POZ domain; and, iii) a six-blade C-terminal propeller
domain formed of canonical kelch motifs. Kelch motifLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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ferent species and grouped into KLHL type proteins. The
human host contains 42 of these KLHL-type proteins [4].
KLHL19, also known as KEAP1 protein, has maximum
homology with Plasmodium K13 protein [5]. Human
KEAP1 protein is a negative regulator of the inducible nu-
clear erythroid 2-related factor 2 (Nrf2)-dependent cyto-
protective response, sequestering Nrf2 in the cytoplasm
under steady state [6,7]. The transcription factor Nrf2
binds to the antioxidant response element (ARE) present
in promoters of genes involved in phase II detoxification
and oxidative stress responses. Nrf2 forms a heterodimer
to activate Maf transcription factor protein that binds to
the ARE and activates transcription through the Maf
recognition element (MARE). KEAP1 is involved Nrf-2
degradation by targeting it for ubiquitination through the
cullin 3 ligase complex. Therefore, it is assumed that
the K13 propeller performs a similar function in the P. fal-
ciparum and mutation in the gene impairs anti-oxidant/
cytoprotective function. However, no orthologue of Nrf2
has been identified in Plasmodium parasite genome [5].
Bangladesh is a malaria hypo-endemic country, sharing
its border with India and Myanmar. Bangladesh has made
great strides in malaria control with a 65% decrease
in total malaria cases and 91% reduction in malaria-
associated mortality from 2008 to 2012. The number of
national cases ranged between 26, 891 and 63, 873 be-
tween 2009 and 2013 according to the National Malaria
Control Programme. High coverage and increased use of
insecticide-treated nets, use of rapid diagnostic tests for
case detection at the community level, anti-malarial
treatments with ACT, and a high number of community
health workers and health facilities have contributed
significantly to this achievement [8]. Ministry of Health
and Family Welfare (MoHFW) has introduced artemether-
lumefantrine (Coartem©) as ACT to treat uncomplicated
falciparum malaria since 2004 [9] and the process has ac-
celerated with impetus from the Global Fund in 2007 [8].
Artemisinins are considered as the last line of defense
against P. falciparum-associated malaria. Since country-
wide implementation from 2004, ACT remains quite suc-
cessful in Bangladesh [10-12]. No day 3 positivity data is
available at this time to objectively gauge ACT efficacy.
However, the increase of heritable artemisinin-resistant
malaria parasite in the Thai-Cambodia border [13], and
subsequently in the Thai-Myanmar [14] border to
southern Myanmar [15], is worrisome for the
Bangladesh-India-Myanmar tri-country border area.
Exact population movement in this border area is not
defined because huge illegal movements are involved.
Rohinga communities of Myanmar have already formed
several refugee camps in Bangladesh and still their num-
ber is increasing due to civil war in Myanmar. Both trans-
port of resistance via migration and de novo emergence ofartemisinin resistance are possible. Previously, chloro-
quine and sulphadoxine/pyrimethamine-resistant parasites
emerged in Thai-Cambodia border, consequently spread-
ing to sub-Saharan Africa across the Asia [16,17]. Hence,
monitoring of artemisinin resistance in Bangladesh is an
important global health issue. The current study aimed to
identify the presence or absence of mutations in the K13
propeller gene of Bangladeshi P. falciparum clinical iso-
lates in conjunction with structural analysis to assess the
functional implications of mutations present.
Methods
Sample collection
Plasmodium falciparum-infected malaria patients from cor-
responding Upazila health complex (UHC) of seven en-
demic districts of Bangladesh were included in this study.
These districts include Khagrachari (Matiranga UHC),
Rangamati (Rajasthali UHC), Cox’s Bazar (Ramu and Ukhia
UHC), Bandarban (Lama UHC), Mymensingh (Haluaghat
UHC), Netrokona (Durgapur and Kalmakanda UHC), and
Moulvibazar (Sreemangal and Kamalgonj UHC). Informed
consents were obtained from the patients or their legal
guardians in the case of children and assent from children
aged 11–17 years. A total of 296 P. falciparum positive
blood samples confirmed by field and laboratory micros-
copy in between May 2009 and 2013 was collected for this
study. Consent was also taken for future use of blood sam-
ples. The study was approved by the institutional Ethics
Review Committee (ERC) of International Centre for
Diarrhoeal Disease Research, Bangladesh (icddr,b).
Real time PCR and nested PCR
DNA was extracted by Qiagen Blood mini kit (Carlsbad,
CA) from the collected blood specimens. Microscopy re-
sults were confirmed by both real time PCR and nested
PCR [18,19]. If any discrepancies were found by different
diagnostic methods, those samples were excluded from
the study.
K13 propeller gene amplification and sequencing
The K13 propeller gene was amplified by the nested
PCR method described by Ariey et al. [5] with some modi-
fications. The first step of the nested PCR remained un-
altered while for the second round of PCR, annealing
temperature was adjusted to 65.5°C and annealing time
was reduced to 45 sec. Platinum Taq Polymerase (Life
Technologies, Ontario, Canada) was used for all of the
PCR reactions according to its recommended settings.
Amplified products were purified by Qiaquick PCR purifi-
cation kit (Carlsbad, CA) and then sequenced by Applied
Biosystems 3730XL 96 capillary sequencer. ClustalW soft-
ware [20] was used to align all of the sequences under
Unix interface. The sequences in the multiple sequence
alignment was edited manually by Jalview software [21] to
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helped to identify the mismatched bases. The sequence of
K13 propeller gene was obtained from Genbank (ID:
AL844509.2) and used it as reference sequence to locate
the point mutations in the clinical isolates.Protein structure prediction
Amino acid sequences of the wild type and mutated pro-
teins were used to predict the structure of the protein
and effect of mutations found in Bangladeshi clinical
isolates. Phyre2 online protein structure prediction tool
[22] was used for modelling. The chosen template (PDB
ID: 2WOZ) resulted in a model with a confidence score
of 100% based on homology assessment and model pre-
diction quality.Results
Out of 296 microscopically confirmed P. falciparum sam-
ples, 271 (91.56%) were confirmed by both real time PCR
and nested PCR to have pure P. falciparum infection.
Other (n = 25) specimens were excluded from the study.
With nested PCR, 253 (93.35%) amplicons (848 bp) were
obtained from the DNA of 271 samples as visualized after
SYBR®Safe DNA Gel Stain (Invitrogen) staining of the gel.
After ClustalW alignment and Jalview analysis of the re-
trieved sequences, this study found one synonymous and
one non-synonymous mutation in Bangladeshi clinical
isolates (Table 1). Geospatial mapping of the districts from
which samples were obtained are depicted (Figure 1). The
mapping demonstrates that the non-synonymous muta-
tions are in the K13 protein locus of P. falciparum
samples (n = 2) from the Matiranga UHC of Khagrachari
district. Two samples from unrelated individuals living
15 km apart contained the same A578S mutation in the
K13 propeller gene. Genotyping of the isolates using msp1
and msp2 demonstrated the isolates were genetically
distinct (data not shown). Matiranga UHC is close to the
border with India.Table 1 Distribution of samples and non-synonymous mutati
in Bangladesh
District name Upazila Health Complex (UHC) Sam
Bandarban Lama UHC 14
Cox’s Bazar Ramu and Ukhia UHC 74
Netrokona Durgapur and Kalmakanda UHC 10
Mymensingh Haluaghat UHC 2
Khagrachari Matiranga UHC 154
Rangamati Rajasthali UHC 6
Moulvibazar Sreemangal and Kamalganj UHC 11
Total 271
*The mutation A578S was identified in two unrelated individuals with genetically dComputational modeling was performed using the beta-
propeller domain of the btb-kelch protein krp1 (PDB ID:
2WOZ). The resulting model (Figure 2a) resembled
closely the topology and statistics of the predicted model
by Ariey [5] as assessed by sequence alignment to the
coordinates of the template and prediction quality. The
model predicts a 6-bladed propeller structure with hom-
ology to previously characterized kelch domain proteins
[23,24]. Mutational sensitivity prediction by the PHYRE2
Investigator suggests that the A578S mutation observed in
this study is likely to disrupt the P. falciparum K13 pro-
peller protein function. K13-propeller protein mutations
are reported to alter the biological function of the protein
by modification of surface charges that disrupt interac-
tions with other proteins. Superimposition of the hom-
ology models of the wild type and mutated proteins show
qualitatively that A578S mutant (in addition to the known
mutant C580Y seen in South East Asia) is predicted to
cause structural changes in the overall topology of the
protein (Figure 2b). Due to these changes, the function of
the protein with these mutations is quite likely disrupted.
Indeed, these modeling predictions are consistent with the
findings of the study by Ashley [25] who report that mu-
tations of the K13 propeller protein after amino acid
position 440 were associated with a mean increase in
the parasite clearance half-life of 116% (95% CI, 103 to
131; P < 0.001) [26].
Discussion
Although the history of ACT use in Bangladesh dates to
only 2004, the country lies adjacent to countries where
resistance to ACT is emerging. Parasites from South
East Asian countries appear to have a propensity to be-
come multi-drug resistant [3]. Researchers have observed
that mutations such as M476I in the K13 propeller gene
are linked to artemisinin resistance in vitro using the ring
stage assay (RSA) developed specifically to test artemisinin
activity in the test tube [5]. Clinical studies have also
confirmed 17 mutations in the K13 propeller gene wereons by District and Upazila Health Complex (UHC)













Figure 1 Geographical distribution of Plasmodium falciparum K13 gene mutations in this study.
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[5], contrasting data showing high efficacy of ACT in
Bangladesh [10-12] in the Bandarban district. This study
has collected blood specimens from different parts of the
country and evaluated the presence of K13 propeller mu-
tations. Two (0.78%) specimens from unrelated individuals
appear to contain structure-altering mutations (A578S) in
the K13 propeller gene from genetically distinct isolates.
These data suggest that mutations in K13 arise de novo ra-
ther through clonal expansion. The Matiranga UHC in
the district of Khagrachari is in the tri-border area with
Myanmar and India. There is no report of artemisininresistance from India so far. While ACT remains effica-
cious and these mutations are rare based on this surveil-
lance, ACT usage will impose positive selection on the
resistant parasite. It has been suggested that the high
diversity of vector species in Bangladesh [27,28] can con-
tribute to the spread of these mutated strains of P. falcip-
arum. Moreover, a very low rate of transmission can result
in inadequate immunity to clear the parasite that might
have survived after ACT treatment, thereby increasing the
selection pressure on resistant clones [26]. Monitoring of
possible resistant parasite clones is of paramount import-
ance. A limitation of this study is the lack of clinical
Figure 2 Predicted model of the P. falciparum K13 propeller
protein. a) Location of the mutation sites relative to the overall
model of the protein. The beta-propeller domain of the btb-kelch
protein Krp1 (PDB ID: 2WOZ) was used as the modeling template.
b) Superimposition of the homology models of the wild type and
mutated proteins. Areas where the individual colors of the mutants
are illustrated display regions where the mutation affects the
predicted fold. These areas are indicated by the black block arrows.
Mohon et al. Malaria Journal 2014, 13:431 Page 5 of 6
http://www.malariajournal.com/content/13/1/431efficacy data. Also no other genetic markers of resistance
were evaluated.
Protein modelling data suggest that A578S can alter
the function of the K13 propeller protein. A578S is very
close to the C580Y mutation, the major mutation ob-
served in the K13 propeller protein of the Cambodian
isolates [5]. The tracking resistance to artemisinin col-
laboration (TRAC) group also found the A578S muta-
tion in one specimen within their study areas but this
mutation was not associated with increased parasite clear-
ance half-life [25]. Importantly, mutations such as A578S
lie after the position 400 and alter the structure of K13
significantly and thus may have an effect on artemisinin ac-
tivity. Crude measures like parasite clearance time are
multi-factorial phenotypes influenced by pharmacokinetics,immunity, and patient adherence, and thus may not imme-
diately correlate with important mutations without a large
sample size. Ramu UHC in Cox’s Bazar district is one of
the TRAC study sites where slow clearing parasites were
observed without any mutation on K13 propeller gene
which again speaks to the multi-factorial nature of this
phenotype. Similarly, clinical specimens collected from
Ramu in the study presented here did not demonstrate
mutations in the K13 gene. Takala-Harrison [29] re-
cently demonstrated that the vast majority of isolates in
their collection were wild type at the K13 locus with
A578S not present.
Conclusion
Up-to-date information on whether artemisinin resistance
has already disseminated or independently emerged be-
yond the Cambodia-Thailand region is a significant issue.
The WHO, with the help numerous collaborators, has de-
clared the global plan for artemisinin resistance contain-
ment [30]. If resistance were limited to a small, well-
defined area, then elimination of drug-resistant malaria
from these regions would be possible [31]. Unfortunately,
resistance is not limited to the Thai-Cambodian border, it
has already spread to the Vietnam, Laos and Myanmar
border [25]. Our data demonstrate that mutations strongly
linked to artemisinin resistance are not present at this
time in Bangladesh.
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